Category: Events

The UW Drug Interaction Database team will be attending the ISSX/MDO Meeting in Seattle, WA on Sept 11-14, 2022. In addition to our booth #24, we hope to meet you at our poster #P56:

• “Enzyme- and transporter-mediated clinical drug interactions with drugs approved by the U.S Food and Drug Administration in 2021: What can be learned from New Drug Application reviews?”; presented by Dr. Jingjing Yu on Sept 13 in the Fifth Avenue Room.

The UW Drug Interaction Database team will be attending the 12^th International ISSX Meeting in Portland next week. In addition to our booth #316, we hope to meet you at one of our posters:

• “Main mechanisms of PK DDIs triggering label recommendations for drugs approved by FDA in 2018”; presented by Dr. Jingjing Yu on July 29 at 11am

• “Variability of OATP1B1/1B3 in vitro inhibition constants and the resulting impact on clinical evaluation”; presented by Dr. Savannah McFeely on July 31st at 12:30pm.

Drs. Jingjing Yu, Sophie Argon, and Savannah McFeely will speak at the upcoming 22nd International Conference on Drug-Drug Interactions, June 20-22, Seattle WA.

Also, visit our exhibit booth during the conference to learn about new developments and upcoming features.

Dr. Jingjing Yu will be contributing to the Inaugural Asian DDI Conference scientific program (December 3-6, 2018 – Hong Kong) with a presentation entitled “Mechanistic Analysis of the Risk of Pharmacokinetic Drug-Drug Interactions with Drugs Recently Approved by the US Food and Drug Administration“.

The DIDB team will be exhibiting at the upcoming 18th International Conference on Drug-Drug Interactions in Seattle on June 29-July 1, 2014, and will contribute to the scientific program with two presentations:

* Critical Review of the 2014-2015 Literature (Dr. Sophie Argon)

* New Molecular Entities Approved by FDA in 2014: Review of In Vitro and In Vivo Data (Dr. Jingjing Yu)

Dr. Ragueneau-Majlessi will be chairing the session entitled “NDA and Literature Update” on June 29th.

The DIDB team will be exhibiting at the 17th International Conference on Drug-Drug Interactions in Seattle on June 30-July 2, 2014, and will contribute to the scientific program with two presentations:

* Critical Review of the 2013-2014 Literature (Dr. Sophie Argon)

* New Molecular Entities Approved by FDA in 2013: Review of In Vitro and In Vivo Data (Dr. Jingjing Yu)

Dr. Ragueneau-Majlessi will be chairing the session entitled “NDA and Literature Update” on June 30th.